Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market (2026-2033) | NASH Drug Development, Liver Fibrosis Drugs, Drug Approvals, & Global Market Insights

AI Briefing

• – Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market expected to reach $7.64 billion by 2031, growing at 21.8% CAGR from 2024 to 2031.
• – NASH drug development and liver fibrosis drugs to drive market growth
• – Increased focus on non-alcoholic fatty liver disease treatment to expand market opportunities